USFDA grants generic antibiotic medication from Glenmark Pharma approval

USFDA grants generic antibiotic medication from Glenmark Pharma approval

The US health authorities has given Glenmark Pharmaceuticals permission to market a generic antibiotic medicine, the company announced on Tuesday.

According to a statement from Glenmark Pharma, the business has gained final FDA approval for Clindamycin Hydrochloride Capsules, a substitute for Pfizer’s Cleocin capsules.

Glenmark Pharmaceuticals Inc. will distribute Clindamycin Hydrochloride Capsules from Glenmark in strengths of 75 mg, 150 mg, and 300 mg in the US, it was noted.

The Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, generated yearly sales of about USD 33.6 million, according to IQVIA sales statistics for the 12-month period ending January 2023.

On the BSE, Glenmark shares were trading 0.12 percent higher at Rs 426.10 per share.

About Glenmark Pharma:

Glenmark was established with the goal of becoming a preeminent, fully integrated, international pharmaceutical firm. We have a sizable presence in markets across emerging economies, including India, through our branded generics business.

For More Latest News Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *